test3

Clinical Trial: INBRX-209

Trial Status: Open
Disease Type: Sarcoma
Trial ID INBRX-209
Sponsor ID Inhibrx

A Randomized, Blinded, Placebo-Controlled, Phase 2 Study of INBRX-109 in Unrsectable or Metastatic Conventional Chondrosarcoma

2 Locations

Locations

Fairfax Office

Gainesville Office

Learn More About This Trial
Other Relevant Trials
Trial ID HFB-301001
Sponsor ID HFB-301001-01

A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors

Principal Investigator
M. Adham Salkeni, MD, FRCPC
1 Location
Trial ID HFB-200301
Sponsor ID HFB-200301-01

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors